biostudies-literatureUnknown7(1)Harada T<h4>Objective</h4>To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.<h4>Design</h4>Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.<h4>Subjects</h4>Japanese patients aged ≥20 and <50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).<h4>Intervention</h4>Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.<h4>Main outcome measures</h4>Change in EF&S reports38-45https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905615biostudies-literatureImpact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.PMC12905615Harada TMeguro KKobayashi TNogami MIizuka MManda CHirayama MfalseImpact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.<h4>Objective</h4>To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.<h4>Design</h4>Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.<h4>Subjects</h4>Japanese patients aged ≥20 and <50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).<h4>Intervention</h4>Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.<h4>Main outcome measures</h4>Change in E2026-01-01T00:00:00Z2026 Feb2026-07-15T16:35:38.367Z2026-07-07T03:08:39.476ZS-EPMC129056154169426210.1016/j.xfre.2025.12.002